Futura Medical (AIM:FUM) upsized its retail share offer to £200,000 after the tranche closed significantly oversubscribed.
The AIM-listed company behind Eroxon, the over-the-counter topical gel for erectile dysfunction, had originally targeted £150,000 from the retail tranche on the BookBuild platform.
The retail offer now sees 100 million new shares issued at 0.2p each.
Applicants had their allocations scaled back proportionately based on existing shareholdings and application size.
The upsized retail offer forms part of a wider capital raise, with the firm placing, conditional placing, conditional subscription and retail offer together raising approximately £1.8 million before expenses.
News Intelligence what this means for the company
Futura Medical's retail share offer closed oversubscribed, prompting an upsize from £150,000 to £200,000 and lifting total fundraising to approximately £1.8 million. The raise, which extends cash runway into February 2027, follows the company's launch of a formal sale process in early September; retail investor demand suggests confidence in the capital structure, though the company remains pre-revenue on its lead products and dependent on partner execution.
The oversubscription validates retail appetite for the capital raise and supports the stated runway extension, but does not alter the core investment case: Futura remains cash-constrained, reliant on commercial partners (Market Performance Group for US Eroxon, Haleon transition completed), and awaiting US FDA clearance for Eroxon in the second half of the year. The formal sale process remains the material catalyst.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
